Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 15...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Hypertension 2015-01, Vol.2015 (2015), p.97-108
Main Authors: Malacco, Ettore, Parati, Gianfranco, Omboni, Stefano
Format: Article
Language:English
Subjects:
Cholesterol
Clinical Study
Complications and side effects
Diuretics
Dosage and administration
Drug dosages
Health risk assessment
Heart attacks
Heart failure
Hydrochlorothiazide
Hypertension
Irbesartan
Lipids
Mortality
Risk factors
Substance abuse treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p = 0.778 ) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p = 0.781 ) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.
ISSN:2090-0392
2090-0384
2090-0392
DOI:10.1155/2015/139465